Physician profile
Robert J Hurst
NPI 1972579142
$870.63
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2022: $167 · 2023: $360 · 2024: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.12 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $136.42 | 2019-2023 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $118.05 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $94.37 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $52.50 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.83 | 2022-2023 | Jardiance |
| Glaxosmithkline, LLC. | $41.25 | 2023 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $30.67 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.73 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $24.96 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $19.93 | 2023 | Freestyle Libre 3 |
| Pfizer INC. | $19.05 | 2019 | |
| Hikma Pharmaceuticals USA | $17.00 | 2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $14.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.44 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.